ZG005
Phase 2Biologic
ZG005 is one of 283 biologic programs targeting Patients With Advanced Solid Tumors. It is currently in Phase 2.
10
Indications
14
Total Trials
13
Active Trials
282
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Yervoy
Bristol-Myers SquibbPhase 3
BL-B01D1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
RC148
RRemeGen Co., Ltd.
Phase 3
ZG005
SSuzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Patients With Advanced Solid Tumors3 trials
Neuroendocrine Carcinoma2 trials
Hepatocellular Carcinoma2 trials
A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
Unknown status·—·N/A·NCT06233994·30 enrolled
Advanced Solid Tumors1 trial
5 more indications
Non-Small Cell Lung Cancer1 trial
Lymphoma1 trial
Advanced Biliary Tract Carcinoma1 trial
Cervical Carcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ZG005. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details